Search

Displaying results 4981 - 4990 of 10000 in total
  1. Drug

    Nisevokitug

    go.drugbank.com/drugs/DB17561
    Investigational

    Nisevokitug is a monoclonal antibody targeted against transforming growth factor beta (TGFβ) under investigation in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety

  2. Drug

    QL1706

    go.drugbank.com/drugs/DB17562
    Investigational

    QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies.

  3. Drug

    Belvarafenib

    go.drugbank.com/drugs/DB17568
    Investigational

    Synonyms: 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno(3,2-d)pyrimidine-7-carboxamide, Thieno(3,2-d)pyrimidine-7-carboxamide, 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methyl-5-isoquinolinyl)-Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  4. Drug

    DCVax-L

    go.drugbank.com/drugs/DB17580
    Investigational

    DCVax-L is a personalized immunotherapy comprising an autologous vaccine with dendritic cells loaded _in vitro_ with autologous tumour lysate.

    Synonyms: DCVax-L
  5. Drug

    Ad-CEA vaccine

    go.drugbank.com/drugs/DB17581
    Investigational

    Ad-CEA vaccine is a cancer immunotherapy composed of carcinoembryonic antigen (CEA).

  6. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    [A257714] While effective, disease progression may occur 6 to 8 months after treatment with currently approved FGFR inhibitors is started, and this effect is usually associated with on-target resistance … KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs).

  7. Drug

    Loxoribine

    go.drugbank.com/drugs/DB17589
    Experimental

    Synonyms: 7-Allyl-7,8-dihydro-8-oxoguanosineCategories: Heterocyclic Compounds, 2-Ring
  8. Drug

    Etuvetidigene Autotemcel

    go.drugbank.com/drugs/DB17593
    ApprovedInvestigational

    [L54693] WAS is a rare X-linked disorder caused by a mutation in the gene encoding the WAS protein, leading to a compromised immune system. … [L54698] First approved by the FDA on December 9, 2025, etuvetidigene autotemcel is used to treat Wiskott–Aldrich syndrome (WAS) in selected pediatric and adult patients.

  9. Drug

    Marnetegragene autotemcel

    go.drugbank.com/drugs/DB17595
    Approved

    Severe leukocyte adhesion deficiency-I (LAD-I) is a genetic disorder leading to frequent life-threatening infections and high fatality risks among affected pediatric patients. … [L56116, A275467] Allogeneic hematopoietic stem cell transplant is a curative option but is limited by issues such as donor availability, a high incidence of graft-versus-host disease, and graft failure

    Synonyms: Hematopoietic stem cells modified with a lentiviral vector containing the CD18 (integrin beta 2) gene, Autologous CD34+ cells transduced ex vivo with a lentiviral vector (Chim-CD18-WPRE) encoding the ITGB2 gene
  10. Drug

    NP-6A4

    go.drugbank.com/drugs/DB17599
    Experimental

    NP-6A4 is a peptide designed to specifically bind and activate angiotensin II receptor type 2 (AT2R). It has an Orphan Drug designation from the FDA for pediatric cardiomyopathy.[A258523]